Literature DB >> 8166645

Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase.

D J Grainger1, P R Kemp, C M Witchell, P L Weissberg, J C Metcalfe.   

Abstract

Transforming growth factor beta 1 (TGF-beta 1) decreased the rate of proliferation of rat aortic vascular smooth muscle cells (VSMCs) stimulated with serum showing a maximal effect at > 5 ng/ml (200 pM). However, it did not reduce the proportion of cells which passed through S phase (> 90%) and entry into S phase was delayed by less than 3 h. The proportion of cells passing through M phase (> 90%) was also unaffected, but entry into mitosis was delayed by approx. 24 h. This increase in cell cycle time was therefore due mainly to an increase in the G2 to mitotic metaphase period. Addition of TGF-beta 1 late in G1 or late in S phase failed to delay the onset of mitosis, but the presence of TGF-beta 1 between 0 and 12 h after the addition of serum to quiescent cells was sufficient to cause the maximal delay in mitosis of approx. 24 h. The role of cyclic AMP in the mechanism of the TGF-beta 1 effects on the cell cycle was examined. Entry into mitosis was preceded by a transient 2-fold increase in cyclic AMP concentration and TGF-beta 1 delayed both this increase in cyclic AMP and entry into mitosis to the same extent. Addition of forskolin or 8-(4-chlorophenylthio)-cyclic AMP to cells 30 h after stimulation with serum completely reversed the increase in duration of G2 in the presence of TGF-beta 1, suggesting that the rise in cyclic AMP levels which precedes mitosis might trigger entry of the VSMCs into M phase. Addition of forskolin late in S phase (26 h after stimulation with serum) advanced the entry of the cells into M phase and they divided prematurely. This effect was unaffected by the addition of cycloheximide with the forskolin; however, the effect of forskolin on cell division was completely inhibited when cycloheximide was added late in G1. TGF-beta 1 prevented the loss of smooth-muscle-specific myosin heavy chain (SM-MHC), which occurs in primary VSMC cultures in the presence or absence of serum, and the cells proliferated while maintaining a differentiated phenotype. However, TGF-beta 1 did not cause re-differentiation of subcultured VSMCs which contained very low amounts of SM-MHC and the effect of TGF-beta 1 in extending the G2 phase of the cell cycle is exerted independently of its effect on differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166645      PMCID: PMC1138046          DOI: 10.1042/bj2990227

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase.

Authors:  H Y Lin; X F Wang; E Ng-Eaton; R A Weinberg; H F Lodish
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

2.  Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex.

Authors:  J Massagué
Journal:  J Biol Chem       Date:  1985-06-10       Impact factor: 5.157

3.  Type beta transforming growth factor is an inhibitor of myogenic differentiation.

Authors:  J Massagué; S Cheifetz; T Endo; B Nadal-Ginard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

4.  Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells.

Authors:  J Pfeilschifter; S M D'Souza; G R Mundy
Journal:  Endocrinology       Date:  1987-07       Impact factor: 4.736

Review 5.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

6.  Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells.

Authors:  A S Rovner; R A Murphy; G K Owens
Journal:  J Biol Chem       Date:  1986-11-05       Impact factor: 5.157

7.  The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors.

Authors:  S Cheifetz; J A Weatherbee; M L Tsang; J K Anderson; J E Mole; R Lucas; J Massagué
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

Review 8.  Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis.

Authors:  G R Campbell; J H Campbell
Journal:  Exp Mol Pathol       Date:  1985-04       Impact factor: 3.362

9.  Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.

Authors:  R Derynck; J A Jarrett; E Y Chen; D H Eaton; J R Bell; R K Assoian; A B Roberts; M B Sporn; D V Goeddel
Journal:  Nature       Date:  1985 Aug 22-28       Impact factor: 49.962

10.  Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells.

Authors:  T Masui; L M Wakefield; J F Lechner; M A LaVeck; M B Sporn; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

View more
  17 in total

1.  Pathology of urethral fibromuscular system related to parturition-induced stress urinary incontinence and TGF-β1/Smad pathway.

Authors:  Guang-Yong Li; Wan-Shou Cui; Feng Zhou; Zhe-Zhu Gao; Hua Xin; Tao Liu; Wei-Ren Li; Yan-Qing Gong; Guang-Yi Bai; Ying-Lu Guo; Zhong-Cheng Xin
Journal:  Mol Cell Biochem       Date:  2012-02-04       Impact factor: 3.396

2.  Myogenic growth factors can decrease extraocular muscle force generation: a potential biological approach to the treatment of strabismus.

Authors:  Brian C Anderson; Stephen P Christiansen; Linda K McLoon
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

3.  Differential regulation of extracellular signal-regulated protein kinases (ERKs) 1 and 2 by cAMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells.

Authors:  R Cospedal; M Lobo; I Zachary
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

Review 4.  The latent transforming growth factor beta binding protein (LTBP) family.

Authors:  R Oklü; R Hesketh
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

5.  Induced elastic matrix deposition within three-dimensional collagen scaffolds.

Authors:  Lavanya Venkataraman; Anand Ramamurthi
Journal:  Tissue Eng Part A       Date:  2011-08-29       Impact factor: 3.845

6.  Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.

Authors:  T Nakaoka; K Gonda; T Ogita; Y Otawara-Hamamoto; F Okabe; Y Kira; K Harii; K Miyazono; Y Takuwa; T Fujita
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

7.  Thrombospondin 1 does not activate transforming growth factor beta1 in a chemically defined system or in smooth-muscle-cell cultures.

Authors:  D J Grainger; E K Frow
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

8.  Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries.

Authors:  Ick-Mo Chung; Junwoo Kim; Youngmi K Pak; Yangsoo Jang; Woo-Ick Yang; Innoc Han; Seung-Jung Park; Seong-Wook Park; Jooryung Huh; Thomas N Wight; Hikaru Ueno
Journal:  Int J Cardiol       Date:  2010-01-06       Impact factor: 4.164

9.  Ascending Aortic Proaneurysmal Genetic Mutations with Antiatherogenic Effects.

Authors:  Alexander Curtis; Tanya Smith; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2015-08-17

10.  Rapid up-regulation of alpha4 integrin-mediated leukocyte adhesion by transforming growth factor-beta1.

Authors:  Rubén A Bartolomé; Francisco Sanz-Rodríguez; Mar M Robledo; Andrés Hidalgo; Joaquin Teixidó
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.